Vaxxinity announces first subjects dosed in phase 1 clinical trial of ub-313 for preventive treatment of migraine

Dallas, sept. 13, 2022 (globe newswire) -- vaxxinity, inc. (nasdaq: vaxx), a u.s. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first subjects have been dosed in a phase 1 clinical trial of ub-313, a vaccine targeting calcitonin gene-related peptide (cgrp), for the preventive treatment of migraine.
VAXX Ratings Summary
VAXX Quant Ranking